Novo Nordisk has announced that it's cutting the price of pre-filled insulin pens and vials by up to 75 percent for people living with diabetes starting in January 2024.
"We have been working to develop a sustainable path forward that balances patient affordability, market dynamics, and evolving policy changes," said Steve Albers, senior vice president of market access and public affairs at Novo Nordisk, Inc. "Novo Nordisk remains committed to ensuring patients living with diabetes can afford our insulins, a responsibility we take seriously."
Earlier this month, rival drugmaker Eli Lilly announced plans to reduce insulin prices by 70 percent and cap patient out-of-pocket costs for insulin at $35 per month.
The Biden administration has put public pressure on drugmakers to make medically necessary insulins more affordable. Novo Nordisk notably did not put a cap on out-of-pocket expenses.
Novo Nordisk will lower the price for four different brands, including NovoLog® and NovoLog® Mix 70/30 by 75 percent and Novolin® and Levemir® by 65 percent.
Teva Pharmaceuticals saw shares rise during Thursday's session after announcing its growth strategy. Richard Francis, president and CEO of Teva Pharmaceuticals, joined Cheddar News to discuss its pipeline of products that the company expects to help revenue.
Brian Jacobsen, chief economist with Annex Wealth Management, joined Cheddar News to discuss the positive sessions for the stock market as investors were optimistic of a debt ceiling deal ahead of the June 1 deadline.
The Walt Disney Co. says it's scrapping plans to build a new campus in central Florida and relocate 2,000 employees from Southern California to work in digital technology, finance and product development.
